|
Signal.
AI & Tech briefing · Friday, 19 June 2026
OpenAI is doubling down on life sciences—genetic disease diagnosis, medicinal chemistry, health benchmarks—while the field grapples with safety and measurement. Meanwhile, infrastructure plays like Baseten and Amazon's chip ambitions suggest the real competition isn't model weights anymore, it's compute. These are the bets that separate lasting builders from the noise.
|